Evaxion Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Evaxion kazanç ve gelirinin sırasıyla yıllık 0.9% ve 17% oranında artması tahmin edilirken, EPS'nin yıllık 92.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

0.9%

Kazanç büyüme oranı

92.46%

EPS büyüme oranı

Biotechs kazanç büyümesi	22.4%
Gelir büyüme oranı	17.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	09 Mar 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Mar 11Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Aug 10

Evaxion Biotech announces new CEO as Lars Wegner resigns

Aug 02

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:EVAX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	16	-7	-19	-15	3
12/31/2027	17	-2	-18	-16	4
12/31/2026	4	-13	-16	-14	4
12/31/2025	8	-8	-7	-7	N/A
9/30/2025	8	-5	N/A	N/A	N/A
6/30/2025	3	-12	-12	-12	N/A
3/31/2025	3	-13	N/A	N/A	N/A
12/31/2024	3	-11	-13	-13	N/A
9/30/2024	3	-11	N/A	N/A	N/A
6/30/2024	0	-15	-15	-15	N/A
3/31/2024	0	-15	N/A	N/A	N/A
12/31/2023	0	-22	-18	-18	N/A
9/30/2023	N/A	-24	-22	-22	N/A
6/30/2023	N/A	-25	-24	-24	N/A
3/31/2023	N/A	-24	N/A	N/A	N/A
12/31/2022	N/A	-23	-26	-26	N/A
9/30/2022	N/A	-25	-25	-24	N/A
6/30/2022	N/A	-24	-25	-24	N/A
3/31/2022	N/A	-26	-27	-26	N/A
12/31/2021	N/A	-25	-23	-22	N/A
9/30/2021	N/A	-20	-23	-22	N/A
6/30/2021	N/A	-19	-20	-19	N/A
3/31/2021	N/A	-16	-14	-14	N/A
12/31/2020	N/A	-15	-13	-12	N/A
9/30/2020	N/A	-14	-10	-10	N/A
12/31/2019	N/A	-11	-7	-7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EVAX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: EVAX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: EVAX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: EVAX şirketinin gelirinin (yıllık 17% ) US pazarından (yıllık 10.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EVAX şirketinin gelirinin (yıllık 17% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EVAX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/29 14:20
Gün Sonu Hisse Fiyatı	2026/03/27 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza ilişkin kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Evaxion A/S 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Swayampakula Ramakanth	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Thomas Flaten	Lake Street Capital Markets, LLC

Evaxion Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates increase by 331%

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

Consensus revenue estimates increase by 33%, EPS downgraded

Forecast to breakeven in 2025

Forecast to breakeven in 2024

Recent updates

Evaxion A/S, Annual General Meeting, Apr 16, 2026

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases

Evaxion A/S to Report Q3, 2026 Results on Nov 19, 2026

Evaxion A/S to Report Q3, 2025 Results on Nov 06, 2025

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces New Two-Year Unprecedented Clinical Efficacy Data of Its Personalized Cancer Vaccine EVX-01 in Patients with Advanced Melanoma

Evaxion A/S to Present New Biomarker Data for AI- Designed Personalized Cancer Vaccine EVX-01 At the SITC 2025 Annual Meeting

Evaxion A/S to Report Q2, 2025 Results on Aug 14, 2025

Evaxion A/S to Present Two-Year Clinical Efficacy Data from Phase 2 Trial with AI- Designed Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2025

Evaxion A/S Announces CEO Changes

Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion A/S to Report Q1, 2025 Results on May 27, 2025

Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of Ai- Designed Personalized Cancer Vaccine Evx-01

Evaxion Biotech A/S Presents striking EVX-01 Data at the AACR Annual Meeting

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $4.48 million.

Evaxion Biotech A/S Extends Phase 2 Trial with AI-Immunology™?

Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination

Evaxion Completes Dosing in Phase 2 Trial with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Establishes New AI-Derived Precision Cancer Vaccine Concept

Evaxion Biotech A/S has filed a Follow-on Equity Offering in the amount of $12.5 million.

Evaxion Announces Positive Preclinical Data for Cytomegalovirus (CMV) Vaccine Program EVX-V1

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Negative shareholders equity

Evaxion Biotech A/S to Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source of Ai-Discovered Targets

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S Announces Encouraging Initial Phase 2 Clinical Data on its Personalised Cancer Vaccine EVX-01

New and Exciting Clinical Data on Evaxion's Ai-Immunology™?-Based Personalized Cancer Vaccines to Be Presented

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion Biotech A/S Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company

Evaxion Biotech A/S Announces New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S announced that it expects to receive $20 million in funding from Negma Group Investment Ltd

Evaxion Biotech A/S Plans to Announce the Interim Results of the Clinical Phase 2 Study with EVX-01 in Patients with Metastatic Melanoma in Fourth Quarter 2023

Evaxion Unveils Genetic Adjuvant Technology to Boost Vaccines

Forecast to breakeven in 2024

Evaxion Unveils Proprietary Genetic Aduvant Technology to Boost the Effect of Dna and Mrna Vaccines

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S and Pantherna Therapeutics GmbH Announce Promising Preclinical mRNA Vaccine Data

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives Phase IIb Go-Ahead from FDA

Evaxion Biotech A/S Receives Approval from FDA to Proceed with the Clinical Phase 2B Study for Evx-01

Evaxion Biotech Reaches an Important Milestone When Enrolled Its First Patient in Perth, Australia in the Company's Global Phase 2B Clinical Trial of EVX-01

Evaxion Biotech A/S Announces Promising Results from Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02

Price target decreased to US$14.67

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech A/S Enrols First Patient in Phase Iib Melanoma Study